270 related articles for article (PubMed ID: 29309049)
1. B cells as biomarkers: predicting immune checkpoint therapy adverse events.
Liudahl SM; Coussens LM
J Clin Invest; 2018 Feb; 128(2):577-579. PubMed ID: 29309049
[TBL] [Abstract][Full Text] [Related]
2. Early B cell changes predict autoimmunity following combination immune checkpoint blockade.
Das R; Bar N; Ferreira M; Newman AM; Zhang L; Bailur JK; Bacchiocchi A; Kluger H; Wei W; Halaban R; Sznol M; Dhodapkar MV; Dhodapkar KM
J Clin Invest; 2018 Feb; 128(2):715-720. PubMed ID: 29309048
[TBL] [Abstract][Full Text] [Related]
3. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
King GT; Sharma P; Davis SL; Jimeno A
Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
5. Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors.
Fiala O; Sorejs O; Sustr J; Kucera R; Topolcan O; Finek J
Anticancer Res; 2020 Mar; 40(3):1219-1227. PubMed ID: 32132018
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
7. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
[TBL] [Abstract][Full Text] [Related]
8. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
[TBL] [Abstract][Full Text] [Related]
10. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
11. Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Day D; Hansen AR
BioDrugs; 2016 Dec; 30(6):571-584. PubMed ID: 27848165
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
Byun DJ; Wolchok JD; Rosenberg LM; Girotra M
Nat Rev Endocrinol; 2017 Apr; 13(4):195-207. PubMed ID: 28106152
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Senant M; Giusti D; Weiss L; Dragon-Durey MA
Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
[TBL] [Abstract][Full Text] [Related]
14. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.
Hoefsmit EP; Rozeman EA; Haanen JBAG; Blank CU
ESMO Open; 2019; 4(4):e000472. PubMed ID: 31423333
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review.
Hommes JW; Verheijden RJ; Suijkerbuijk KPM; Hamann D
Front Oncol; 2020; 10():585311. PubMed ID: 33643899
[TBL] [Abstract][Full Text] [Related]
17. Role of immune-checkpoint inhibitors in lung cancer.
Jain P; Jain C; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
[TBL] [Abstract][Full Text] [Related]
18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
19. Endocrine side effects of cancer immunotherapy.
Cukier P; Santini FC; Scaranti M; Hoff AO
Endocr Relat Cancer; 2017 Dec; 24(12):T331-T347. PubMed ID: 29025857
[TBL] [Abstract][Full Text] [Related]
20. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA; Fecher LA; Owens SR; Razumilava N
Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]